<DOC>
	<DOCNO>NCT01600898</DOCNO>
	<brief_summary>In prospective study , investigator implement systematic screen program 3-year follow-up cohort asymptomatic BMPR2 mutation carrier . This study design : - determine predictive factor ( biological , functional , radiological hemodynamic ) development PAH - monitor subject ' clinical , functional , biological , echocardiographic hemodynamic characteristic - ass risk occurrence PAH - screen patient PAH early stage disease offer early management - constitute collection biological sample ( 0 , 12 , 24 month follow-up ) asymptomatic BMPR2 mutation carrier .</brief_summary>
	<brief_title>Screening Pulmonary Arterial Hypertension BMPR2 Mutation Carriers</brief_title>
	<detailed_description>Introduction : Pulmonary arterial hypertension characterize remodel small pulmonary artery lead progressive increase pulmonary vascular resistance result right heart failure ultimately death . The disease diagnose symptomatic , demonstrate existence already advanced form disease . Indeed , simple tool allow early diagnosis PAH disease usually diagnose advanced stage . Diagnostic confirmation PAH base elevation mean pulmonary arterial pressure measure right heart catheterization . Despite development specific treatment recent year , PAH remain disease poor prognosis , cure possible , apart lung transplantation select case . However recent study show specific drug therapy early disease stage could improve prognosis life threaten disease . This seem important establish early diagnosis PAH , especially high-risk population asymptomatic carrier BMPR2 ( Bone Morphogenetic Protein Receptor 2 ) mutation . PAH due BMPR2 mutation autosomal dominant disease incomplete penetrance . Even accurate data literature , estimate 20 % patient BMPR2 mutation develop PAH course life . The implementation genetic counseling National Reference Center Severe Pulmonary Hypertension ( BICETRE Hospital ) allow u propose systematic assessment BMPR2 mutation patient idiopathic familial PAH . In 2012 identify 130 PAH patient carrier BMPR2 mutation . This approach enable detection family risk PAH offer genetic counseling asymptomatic relative BMPR2 mutation . However , data evolution asymptomatic carrier BMPR2 mutation lack . Furthermore , available consensus guideline follow population . To date , possible differentiate asymptomatic subject carry BMPR2 mutation develop PAH never develop disease . However , give high risk subject develop PAH ( risk 20 % 25/million general population ) , limited knowledge characteristic population , seem essential offer prospective follow-up population risk . Aim objective : The main objective study follow prospectively 3 year cohort asymptomatic carrier BMPR2 mutation : - determine predictive factor ( biological , functional , radiological hemodynamic ) development PAH - monitor subject ' clinical , functional , biological , echocardiographic hemodynamic characteristic - ass risk occurrence PAH - screen patient PAH early stage disease offer early management - constitute collection biological sample ( 0 , 12 , 24 month follow-up ) asymptomatic BMPR2 mutation carrier . Methodology : Evaluation subject inclusion inform consent ( Ethics Committee approval obtain since 2011 ) : - Clinical evaluation : dyspnea assess NYHA functional class ( I-IV ) , sign right heart failure - Chest radiograph , electrocardiogram - Right heart catheterization ( subset volunteer ) : measurement mean pulmonary artery pressure , pulmonary artery occlusion pressure ( PAOP ) cardiac output ( CO ) rest exercise - Echocardiography : measurement velocity tricuspid regurgitation ( VIT ) , measurement TAPSE Tei index , pericardial effusion , dilatation hypertrophy right ventricle - Stress Test : VO2 peak VO2 specific , VE minute ventilation , VD / VT dead space , ventilatory reserve , alveolar-arterial gradient , pulse oxygen , PaO2 - Lung function test : measurement DLCO DLNO - Magnetic resonance imaging ( MRI ) measure end systolic diastolic volume right ventricle , right ventricular mass , septal curvature , diameter pulmonary artery , surface right atrium - Biology : Determination plasma NT-proBNP , uric acid , serum sodium , creatinine , PDGF , ET-1 , ET-3 , CRPus , IL-6 , soluble c-kit , CXCL12 , progenitor circulate fibrocytes Subjects evaluate outpatient schedule National Reference Center Severe Pulmonary Hypertension 12 , 24 36 month inclusion symptom appear ( dyspnoea , right heart failure , malaise syncope ) . During consultation , assessment include : clinical evaluation , chest radiograph , electrocardiogram , echocardiogram , stress testing , pulmonary function test , magnetic resonance imaging , biology . To confirm suspicion PAH ass severity , right heart catheterization rest exercise offer accord decision algorithm . Right heart catheterization perform one follow abnormality find : - Dyspnea , malaise unexplained syncope - Tricuspid regurgitation velocity ≥ 2.8 / - Decrease specific peak VO2 ≥ 20 % compare gold standard If diagnosis PAH confirm , patient treat accord recently update recommendation European Respiratory Society European Society Cardiology .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>men woman 18 year old , carrier BMPR2 mutation without know PAH , give informed consent men woman 18 year old , patient know PAH , pregnant woman , adult protect , detainee , people emergency , people refuse unable give inform consent , affiliation regime social security .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asymptomatic carrier BMPR2 mutation</keyword>
	<keyword>follow study</keyword>
</DOC>